Translational Research

Translational Research

Translational research transforms scientific discoveries arising from fundamental studies into clinical applications to improve outcomes for patients with prostate cancer. Members of this team work together to employ innovative new technologies for biomarker discovery, detection and quantification that have been developed independently in internationally-recognized efforts in Alberta and bring them to bear on a common goal – developing better tests for prostate cancer.

The combination of prognostic biomarkers from distinct aspects of prostate cancer progression resulted in a test that is more sensitive, more accurate and more cost effective than current tests for prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by translating novel tests to the clinic that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer. No one dies from prostate cancer that is localized to the prostate – the spread, or metastasis, of prostate cancer is what makes it so dangerous. The five year survival rate for localized prostate cancer in North America is close to 100%, yet this drops to 30% for metastatic disease. The metastasis of prostate cancer is driven primarily by changes in growth factors, extracellular proteases, and the cell migration machinery. Biomarkers that are involved in these processes are prognostic for metastatic prostate cancer and their integration into a single powerful test are the focus of this multi-disciplinary team.

Our team is integrating internationally-recognized efforts in the characterization of tumour cell migration, growth factor signaling and protease-activated receptors to develop novel multiplex tests to more accurately predict outcomes in prostate cancer.

translational-research-image

It’s Movember, time to Grow a Mo for a Bro!

It’s Movember, time to grow your moustache to raise funds and awareness of some serious health risks that men face, like suicide, testicular cancer and prostate cancer. Maybe growing a moustache isn’t your thing? No problem, host a Mo-ment for the men in your life instead!

APCaRI is a key stakeholder in the TrueNTH Global Registry; contributing 92% of the submitted patients in February 2018. Recently described by Evans et al., 2017 in an article published in BMJ Open, this project was established as an international registry with the goal to monitor the care of men with localised prostate cancer from 13 Movember-fundraising countries. Prostate cancer treatment and outcomes for men vary according to where they live, their race and the care they receive. The TrueNTH Global Registry is collecting a dataset based on the International Consortium for Health Outcome Measures (ICHOM) so we can better understand how to improve the care and treatment of men with localized prostate cancer, regardless of ethnicity and geography.

Please check out previous APCaRI blog posts that have talked about Movember (@Movember); the international Mens’ health Awareness charity, and about TrueNTH (@TrueNTH_Canada); a program funded by Prostate Cancer Canada (PCC) and the Movember Foundation that aims to improve the quality of life of men with prostate cancer and their families.

So start growing (or attach) your moustache today to raise funds and awareness to improve mens’ health!

- Perrin Beatty